Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study by Davies, Mary-Ann et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Pediatrics
Open Access Research article
Adherence to antiretroviral therapy in young children in Cape 
Town, South Africa, measured by medication return and caregiver 
self-report: a prospective cohort study
Mary-Ann Davies*1,2, Andrew Boulle2, Tanzeem Fakir1, James Nuttall1 and 
Brian Eley1
Address: 1Red Cross War Memorial Children's Hospital and the School of Child and Adolescent Health, University of Cape Town, Cape Town, The 
Republic of South Africa and 2Infectious Diseases Epidemiology Unit, School of Public Health and Family Medicine, University of Cape Town, 
Cape Town, The Republic of South Africa
Email: Mary-Ann Davies* - Mary-Ann.Davies@uct.ac.za; Andrew Boulle - Andrew.Boulle@uct.ac.za; 
Tanzeem Fakir - tanzeem_faki23@yahoo.co.uk; James Nuttall - James.Nuttall@uct.ac.za; Brian Eley - Brian.Eley@uct.ac.za
* Corresponding author    
Abstract
Background:  Antiretroviral therapy (ART) dramatically improves outcomes for children in Africa;
however excellent adherence is required for treatment success. This study describes the utility of different
measures of adherence in detecting lapses in infants and young children in Cape Town, South Africa.
Methods: In a prospective cohort of 122 HIV-infected children commenced on ART, adherence was
measured monthly during the first year of treatment by medication return (MR) for both syrups and
tablets/capsules. A questionnaire was administered to caregivers after 3 months of treatment to assess
experience with giving medication and self-reported adherence. Viral and immune response to treatment
were assessed at the end of one year and associations with measured adherence determined.
Results: Medication was returned for 115/122 (94%) children with median age (IQR) of 37 (16 – 61)
months. Ninety-one (79%) children achieved annual average MR adherence ≥ 90%. This was an important
covariate associated with viral suppression after adjustment for disease severity (OR = 5.5 [95%CI: 0.8–
35.6], p = 0.075), however was not associated with immunological response to ART. By 3 months on ART,
13 (10%) children had deceased and 11 (10%) were lost to follow-up. Questionnaires were completed by
87/98 (90%) of caregivers of those who remained in care. Sensitivity of poor reported adherence (missing
≥ 1 dose in the previous 3 days) for MR adherence <90% was only 31.8% (95% CI: 10.7% – 53.0%).
Caregivers of 33/87 (38.4%) children reported difficulties with giving medication, most commonly poor
palatability (21.8%). Independent socio-demographic predictors of MR adherence ≥ 90% were secondary
education of caregivers (OR = 4.49; 95%CI: 1.10 – 18.24) and access to water and electricity (OR = 2.65;
95%CI: 0.93 – 7.55). Taking ritonavir was negatively associated with MR adherence ≥ 90% (OR = 0.37;
95%CI: 0.13 – 1.02).
Conclusion: Excellent adherence to ART is possible in African infants and young children and the
relatively simple low technology measure of adherence by MR strongly predicts viral response. Better
socio-economic status and more palatable regimens are associated with better adherence.
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Background
Approximately 85% of the 2.3 million HIV-infected chil-
dren under 15 years worldwide live in sub-Saharan
Africa.[1] While antiretroviral therapy (ART) of children
in Africa has resulted in dramatically improved survival,
clinical, immunological and virological status, less than
15% of children needing ART on the continent currently
receive it. [2-11] Excellent adherence is one of the most
important factors in determining treatment success and
preventing viral resistance, and the need for near-perfect
adherence to lifelong therapy from an early age has been
identified as a major challenge in the administration of
ART to HIV-infected children.[10,12-15] There is concern
about the extent to which this is achievable for children in
resource-limited settings, particularly in the context of the
rapid scale-up of pediatric treatment programs required to
address the HIV burden on children in Africa.[14,16]
Research from rich countries suggests that adherence may
be more complex in children compared to adults due to
many factors including reliance on caregivers who may
themselves be ill or may not be the child's parent, com-
plex dosing regimens, lack of availability of pediatric
fixed-dose combinations, poor drug palatability, difficulty
with taking tablets/capsules and interference with daily
routines. [13,17-23] Adherence estimates of 50 to 75%
have been reported, well below the required 90 to 95% to
achieve optimal viral suppression.[12,13,17-23]
While African adult studies show that good adherence to
ART is possible despite poor social circumstances, there
are limited studies in African children.[16,24-27] Health
service challenges as well as individual factors such as
poor socio-economic circumstances, poor literacy and the
prohibitive cost of liquid drug formulations necessitating
tablet/capsule administration to very young children are
additional potential barriers to adherence in African chil-
dren.[10,15] In Kampala, Uganda, 72% of children aged
2–18 years had adherence ≥ 95% measured with home-
based unannounced pill counts, compared to 89% using
3-day self-reported adherence and 94% using clinic-based
pill counts.[28] Muller et al. similarly found discrepant
results using different measures of adherence in young
children (median age 38 months) in South Africa.[29]
Using electronic means (Medication Event Monitoring
System (MEMS)) to monitor adherence, only 36% of
patients achieved ≥ 95% adherence, in comparison to
91% of caregivers reporting excellent adherence on a vis-
ual analogue scale.[29] The only other published adher-
ence studies of African children include only older
children and measure self-reported adherence only, with
varying results. In Côte d'Ivoire and Uganda, approxi-
mately one third of caregiver-child pairs reported missing
doses and in South Africa, Reddi et al. describe 10% of
children missing ≥ 3 doses during the previous
month.[6,30,31] African studies thus concur with interna-
tional literature that more objective measures of adher-
ence (e.g. unannounced pill counts and MEMS) tend to be
more sensitive to lapses in adherence.[21,32] However,
such measures are not feasible in resource-limited settings
with large-scale programs, and there is a need to deter-
mine the utility of simpler measures of adherence such as
clinic-based pill-counts and self-report in predicting viro-
logical response in the African context. Furthermore, all
published African studies have been conducted over short
periods (≤ 3 months), mostly in older chidren, and may
not reflect longer term adherence patterns in very young
children.
We therefore aimed to measure the level of adherence to
ART in infants and young children during the first year of
treatment using both medication returned as measured at
the clinic and caregiver self-report, to assess the extent to
which such measured adherence predicts viral and immu-
nological outcomes and to identify factors associated with
good adherence.
Methods
Study design, setting and population
This was a prospective cohort study. All HIV infected chil-
dren commenced on antiretroviral triple therapy between
July 2002 and January 2004 (n = 122) as part of the ART
program of the Red Cross Children's Hospital, a tertiary
care institution in Cape Town, South Africa, were eligible
and agreed to participate in the study. The ART program at
the hospital began prior to the official national govern-
ment ART program and was donor funded during this
time. Selection criteria for commencement of ART have
been described elsewhere.[2] Briefly, clinical and immu-
nological criteria as recommended by the 2001 European
treatment guidelines were followed.[33] In addition, the
following limited social criteria needed to be met: having
an identifiable caregiver to administer medication and
attend clinic appointments; resident in Cape Town for at
least 3 months; caregiver compliance with last 3 clinic
appointments and caregiver willingness to comply with
ongoing regular clinic attendance and monitoring. The
majority of children were commenced on stavudine
(d4T), lamivudine (3TC) and efavirenz (EFV – children
>10 kg or >3 years) or ritonavir (RTV – children <10 kg or
<3 years) as no other protease inhibitor was readily avail-
able in suitable formulation and dosage in South Africa at
the time. Children were followed up with monthly clini-
cal visits for the first year. Viral load, CD4 cell count and
percentage were determined using standard laboratory
methods at commencement of ART and after 1 year of
treatment. The definition of undetectable viral load was
<400 copies/ml. The study was approved by the Univer-
sity of Cape Town Research Ethics Committee [Ref: 261/BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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2002], and all parents provided written informed consent
for their and their children's participation.
Measurements of adherence and associated factors
Clinical and socio-demographic characteristics at com-
mencement of ART were determined by the clinician treat-
ing each child and recorded on standardized data
collection forms. Children were retrospectively re-staged
according to medical record information using the WHO
4-stage clinical classification for the purpose of this anal-
ysis.[15] Weight-for-age, height-for-age and weight-for-
height z-scores were calculated with EpiInfo 2000, version
1.0 (Division of Surveillance and Epidemiology, CDC,
Atlanta, Georgia).
Measurement of adherence by medication return (MR)
At every monthly visit for one year, caregivers were
requested to return all empty medicine containers and
unused medication. A dedicated program pharmacist
measured the amount of unused medication volumetri-
cally for syrups/solutions and by pill count for tablets/
capsules. The percentage adherence for each antiretroviral
medication was calculated by dividing actual use (deter-
mined from returned containers and unused medication)
by expected use (determined from the previous month's
script).
A composite measure of annual average percentage adher-
ence by MR was calculated by determining the arithmetic
mean of the percentage adherence for each drug at each
monthly visit. For caregiver-child pairs who did not return
medication at every visit as requested, the annual average
percentage adherence was calculated using the number of
months for which medication was actually returned as the
denominator when determining the arithmetic mean (per
protocol analysis). Sensitivity analysis was additionally
performed assigning adherence <90% for months in
which medication was not returned and recalculating
annual average percentage adherence for children with
missing medication returns. A small amount of extra med-
ication (in excess of what was prescribed) was issued at
each visit so that patients would not be without medica-
tion if drugs were spilled or additional doses required due
to vomiting or spitting out. For a number of medication
returns, therefore, more drug was used than prescribed
(i.e. adherence >100%) so adherence was capped at 100%
per return when calculating annual average adherence. An
uncapped annual average MR adherence was also calcu-
lated for some of the analyses.
Measurement of adherence by questionnaire
A standardized interview was administered by the treating
clinician to each caregiver after the child had completed 3
months of ART. The interview script was based on Pediat-
ric Aids Clinical Trials Group (PACTG) adherence ques-
tionnaires modules 1 and 2 and assessed caregiver's
ability to accurately describe the ART regimen, recall of
missed doses in the past 3 days, difficulties experienced
with giving medication and beliefs about ART.[34,35]
Based on reported missed doses, children were classified
as not fully adherent (NFA) if ≥ 1 dose was missed in the
previous 3 days. Interpreters were used so that interviews
were conducted in the language of the caregiver's choice.
Analysis
All statistical analysis was done using Stata (version 10)
(Stata Corporation, College Station, Texas, USA). The
effects of low annual average (capped) MR adherence,
average (capped) MR adherence in the month immedi-
ately preceding viral load measurement and reported NFA
on viral load suppression and immunological response
were determined using logistic regression models
adjusted for other determinants of outcome. MR adher-
ence was dichotomized as ≥ 90% or <90% as this thresh-
old explained the largest amount of variability in the
outcome. Univariate and multivariate analysis of the asso-
ciation between demographic, social and clinical factors
as well as experiencing problems with giving medication
and annual average MR adherence ≥ 90% were examined
using Wilcoxon rank sum (Mann-Whitney), Student's t-
test, chi2 or Fisher's exact tests and logistic regression mod-
els as indicated. Agreement between MR adherence <90%
and caregiver reported NFA was calculated using the
kappa statistic.
All multivariate models were built by sequentially adding
the next most significant predictor variable from the uni-
variate analysis, and variables with a p-value <0.1 after
adjustment for those already included in the model, or
that changed the OR for variables included in the model
by more than 10%, were retained. Since variables reflect-
ing severity of illness (WHO stage, weight-for-height z-
score, CD4 percent and absolute count and log viral load)
were highly correlated with one another, only the single
most predictive variable, i.e. weight-for-height z-score,
was included in the multivariate models for virological
and immunological outcome. Similarly, only one meas-
ure of socio-economic status (formal housing, access to
water and electricity, access to a refrigerator and employ-
ment) was used at a time in each model, i.e. access to
water and electricity. Only socio-demographic factors and
regimen were included in building the multivariate model
of MR adherence ≥ 90% as the sample size did not allow
for inclusion of clinical factors as well. P-values for all sta-
tistical analyses are reported exactly with no particular cut-
off used to define significance.[36]
At the time that the study was designed, few data on pae-
diatric adherence from resource-constrained countries
were available on which to base sample size calculations.BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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The change from donor-funded ART to the government
ART program necessitated ending of the study as the gov-
ernment program did not fund adherence monitoring. By
this stage the accumulated sample size was sufficient to
detect a 50% reduction in proportion with viral suppres-
sion in those with MR adherence <90% with 90% power,
assuming that 75% of children had MR adherence ≥ 90%.
Results
Medication was returned on at least one occasion for 115/
122 (94%) children who commenced ART with the
remaining children deceased (n = 6) or lost to follow-up
(n = 1) before their first follow-up visit (figure 1). After 1
year, 88 children were alive and remained in care on ART.
Table 1 shows the demographic and clinical characteris-
tics and ART drugs prescribed at baseline. Children were
young with a median age (IQR) of 37 (16 – 61) months.
Although overall socio-economic status was poor with
high levels of caregiver unemployment (73%) and infor-
mal housing (49%), most caregivers (88%) had at least
secondary education and the majority of children (80%)
were from households with access to water and electricity.
Annual average MR adherence
A total of 91/115 (79%) children achieved annual average
MR adherence ≥ 90% with 73% of these having adherence
≥ 95% (figure 2). Only 9 (8%) children had average
adherence for the full year below 80%. These percentages
did not change substantially if adherence <90% was
assigned for missing returns in children not returning
medication on all possible occasions. The number of chil-
dren remaining in care at each month and the proportion
returning medication as requested is shown in figure 3.
There was no change in the proportion of children return-
ing medication over time (p = 0.17). Among only those
children who remained alive and in care for the entire first
year of treatment (excluding those deceased and LFU; n =
88), the proportion with adherence <90% decreased over
time with an OR for having low adherence of 0.91 (95%
CI: 0.87 – 0.96; p = 0.000) for each additional month (fig-
ure 4). Annual average MR adherence <90% was more
likely among the 34/115 (30%) child-caregiver pairs who
failed to return empty medication containers/unused
medication at more than one follow-up visit (OR = 4.97;
95% CI:1.92 – 12.87; p = 0.001).
Relationship between MR adherence and viral/
immunological outcomes
Undetectable viral load was achieved in 62/80 (78%) chil-
dren with annual average MR adherence ≥ 90% compared
to 2/8 (25%) of children with lower adherence (OR =
10.3; 95% CI: 1.92 – 55.7; p = 0.005). In univariate anal-
ysis, other factors significantly associated with viral sup-
pression were less wasting as reflected in higher weight-
for-height z-score, less severe disease (WHO stage 2 or 3 vs
WHO stage 4) and being on a non-ritonavir containing
regimen (Table 2). Since nutritional status is an important
determinant of WHO stage, only weight-for-height z-score
and regimen were included in building an adjusted logis-
tic regression model for the relationship between adher-
ence and viral suppression. After adjustment for wasting,
regimen was no longer associated with viral load out-
come, however adherence ≥ 90% remained an important
covariate associated with viral suppression (Adjusted OR
= 5.5 [95%CI: 0.8–35.6], p = 0.075). Sensitivity analysis
was performed by recalculating average annual adherence
for caregiver-child pairs who did not return medication
for one or more months by assigning adherence <90% for
months in which medication was not returned, and there
remained a significant univariate association between MR
adherence  ≥ 90% and undetectable viral load, and a
strong trend towards an association after adjustment for
baseline weight-for-height z-score. There was no associa-
tion between MR adherence in the month or 2 months
preceding viral load measurement and viral suppression
in either univariate analysis or after adjustment for base-
line weight-for-height z-score. Similarly no association
was found between the proportion of visits in which car-
egivers failed to return medication and viral suppression
in either univariate or adjusted analyses.
The median (IQR) changes in CD4 percent and absolute
count were 10.1% (5.7% – 15.2%) and 393 cells/μl (113
– 654) respectively. There was no association between
annual average MR adherence ≥ 90% and either CD4 per-
cent at 1 year, or change from baseline CD4 percent or
absolute count over 1 year in either univariate analysis or
models adjusted for other determinants of immunologi-
cal response.
Excess MR Adherence
Using the uncapped annual average MR adherence, 47/
115 (40.9%) of children had adherence >100%. This was
more common among children taking ritonavir (30/50
[60%]) compared to those on efavirenz (17/65 [26%]; p
= 0.000). Adherence >100% was also more common in
those 2 years of age or less (28/37 [75.7%]) compared to
older children (19/78 [24.4%]; p = 0.000). This age-
related difference in excess adherence was maintained
after stratifying for ritonavir-based regimen (p = 0.02 and
0.05 for those with ritonavir-based and efavirenz-based
regimens respectively).
Questionnaire responses
Of 98 children alive and in care after 3 months of ART, 87
(90%) completed adherence questionnaires (figure 1).
Annual average MR adherence ≥ 90% was more common
in those who completed questionnaires (59/87 [68%] vs
4/11 [36%]; p = 0.051).BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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Table 1: Social, demographic and clinical characteristics at start of ART according to annual average MR adherence.
Variable All children (n = 122) Adherence ≥ 90% (n = 91) 
(79%)
Adherence<90% (n = 24) 
(21%)
p-value
Median age (months) (IQR) 37 (16 – 61) 37 (16 – 57) 49 (20 – 72) 0.49*
Gender
Female (%) 52 (43) 39 (43) 12 (50) 0.53†
WHO stage
4 (%) 54 (44) 34 (37) 14 (58%) 0.06†
Mean weight-for-age z-score (sd) -2.02 (1.54) -1.82 (1.55) -2.41 (1.37) 0.09‡
Mean height-for-age z-score (sd) -2.71 (1.36) -2.66 (1.36) -2.74 (1.33) 0.78‡
Mean weight-for-height z-score 
(sd)
-0.56 (1.44) -0.31 (1.34) -1.08 (1.42) 0.02‡
Median CD4 percent (IQR) 11.1 (6.9 – 15.0) 11.4 (8.0 – 15.1) 10.1 (4.2 – 14.3) 0.18*
Median CD4 count (IQR) 556 (242 – 908) 592 (273 – 938) 518 (105 – 758) 0.23*
Median Log Viral load (IQR) 5.57 (5.15 – 6.08) 5.44 (5.11 – 6.08) 5.77 (5.30 – 6.06) 0.55*
Primary caregiver
Mother (%) 107 (88) 79 (87) 21 (88) 0.72§
Not mother (%) 12 (10) 9 (10) 3 (13)
Unknown (%) 3 (2) 3 (3) 0 (0)
Median age of caregiver (IQR) 29 (26 – 32) 30 (26 – 32) 28 (25 – 35) 0.58*
Father provides financial support
Yes (%) 48 (39) 37 (41) 9 (38) 0.8†
No (%) 70 (57) 51 (56) 14 (58)
Unknown (%) 4 (3) 3 (3) 1 (4)
Caregiver has secondary education
Yes (%) 107 (88) 83 (91) 18 (75) 0.03†
No (%) 11 (9) 6 (7) 5 (21)
Unknown (%) 4 (3) 2 (2) 1 (4)
Caregiver employed
Yes (%) 27 (22) 23 (25) 4 (17) 0.37†
No (%) 89 (73) 64 (70) 19 (79)
Unknown (%) 6 (5) 4 (4) 1 (4)
Caregiver/child receives social 
grant
Yes (%) 69 (57) 55 (60) 11 (46) 0.16†
No (%) 51 (42) 34 (37) 13 (54)
Unknown (%) 2 (2) 2 (2) 0 (0)
Formal housing
Yes (%) 62 (51) 50 (55) 8 (33) 0.06†
No (%) 60 (49) 41 (45) 16 (67)
Access to water and electricity
Yes (%) 97 (80) 76 (84) 15 (63) 0.024†
No (%) 25 (20) 15 (16) 9 (38)
Access to working refrigerator
Yes (%) 85 (70) 66 (73) 12 (50) 0.036†
No (%) 37 (30) 15 (16) 12 (50)
Medication
d4T (%) 110 (90) 81 (89) 22 (92) 1.00*
AZT (%) 11 (9) 8 (9) 3 (13) 0.70*
3TC (%) 117 (96) 88 (97) 22 (92) 0.28*
ddI (%) 4 (3) 3 (3) 1 (4) 1.00*
Efavirenz (%) 67(55) 55 (60) 10 (42) 0.08†
Ritonavir (%) 55 (45) 36 (40) 14 (58) 0.10†
*Wilcoxon rank sum test
‡Student's t-test
†Chi2 test
§Fisher's exact testBMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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Reported missed doses
NFA (missing ≥ 1 dose in the previous 3 days) was present
in 12/87 (13.8%) children, and was more common in
those whose MR adherence for that month was <90% (7/
22 [31.8%]) vs 5/62 [8.1%]; p = 0.006). Nevertheless, the
sensitivity of NFA for poor MR adherence in the preceding
month was only 31.8% (95% CI: 10.7% – 53.0%) and
agreement between the two measures was only slightly
better than that expected by chance (κ = 0.278; p = 0.003).
There was no association between NFA and viral response
at 1 year (p = 0.965). Although 38/87 (43.7%) of caregiv-
ers were unable to describe how to give their child's ART
regimen exactly, this was not associated with either NFA
or MR adherence <90% (p = 0.88 and p = 0.68 respec-
tively).
Experience with giving medication
A notable number of caregivers (33/87 [38.4%]) experi-
enced problems with giving ART medication. Poor palata-
bility of medication was the most common problem
(21.8% of caregivers), with 68% of these being attributed
to ritonavir. Change in daily routine was a problem for
12.6% of caregivers. Experiencing problems with giving
medication did not affect reported (OR = 2.13; 95%CI:
0.59 – 7.65; p = 0.32) or MR adherence (OR = 0.61;
95%CI: 0.22 – 1.65; p = 0.32) in the month in which
problems were reported, but was associated with annual
average MR adherence <90% (OR = 3.07; 95% CI: 0.91 –
10.38; p = 0.06).
Most (65/87 [74.7%]) caregivers used at least one method
to assist with remembering and giving medication. The
most commonly used aids were activities of daily living
reminders (35 [40%]) and treatment partners (23 [26%]).
While the vast majority of caregivers (81 [93%]) believed
that ART medication was improving their child's health, a
significant number (24 [28%]) were unsure or believed
that their children would not deteriorate if ART was
Profile of study Figure 1
Profile of study.
Children commenced on ART 
(n = 122)
No medication returns for 7 children 
because deceased (n=6) or lost to 
follow-up (n=1) within first month of 
ART. 
Medication returned on at least one 
occasion for 115 children
Median (IQR) occasions of MR: 12 (9 – 12)*
Adherence questionnaires after 
3 months of ART completed by 87/98 
caregiver-child pairs alive and in care at 
3 months.
Reasons for not completing questionnaire:
Deceased or not in care: 24/122 (20%)
(13 deceased; 11 lost to follow-up)
No reason given: 10/98 (10%)
Child in institution: 1/98 (1%)
Viral load and CD4 count determined for all 88/122 (72%) 
children alive and in-care after 1 year of ART
Deceased: 19 (16%)
Lost to follow-up: 12 (10%)
Treatment stopped because of poor adherence: 2 (2%)
Transferred to another facility: 1 (1%)
*Medication was returned on all possible occasions for 50% of childrenBMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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stopped. Caregiver beliefs did not influence adherence by
any measure.
Determinants of annual average MR adherence ≥ 90%
Socio-demographic variables most strongly associated
with annual average MR adherence ≥ 90% on univariate
analysis were caregivers having secondary education and
household access to water and electricity as well as a
refrigerator (tables 1 and 3). Having secondary education
was not significantly associated with any of the indicators
of socio-economic status. Being on an efavirenz-based
regimen was less strongly associated with good adherence.
Secondary education of the caregiver and household
access to water and electricity were both independent
socio-demographic predictors of annual MR adherence ≥
90%, while taking ritonavir was negatively associated with
MR adherence ≥ 90%.
Discussion
This study extends to infants and young children the find-
ing that good adherence to ART in Africa is achievable
with nearly 80% of children obtaining average MR adher-
ence ≥ 90% over the first year of ART. [16,25,26,28] This
is at least as good as pediatric adherence in rich coun-
tries.[13,17-22] This excellent adherence occurred despite
nearly 40% of caregivers experiencing subjective difficulty
with administering medication. Secondary education,
access to water and electricity and a non-ritonavir based
regimen were all independently associated with better
adherence. This study demonstrates that although clinic-
based medication measures may not be as sensitive as
unannounced home-based measures or MEMS monitor-
ing to detect poor adherence, they are still strongly predic-
tive of virologic response. Annual average MR adherence
≥ 90% was associated with a greater than 5 fold increased
likelihood of suppressing viral load at the end of the year.
The excellent adherence seen in our study may, however,
not be representative of current pediatric adherence in
Africa as ART is scaled up. These were the first children to
receive ART at our tertiary care institution and many were
well-known to the HIV service as adherent with other
medications and clinic visits. In addition, the social crite-
ria used to determine ART eligibility may have further
selected those patients more likely to be adherent. Fur-
thermore, treatment was donor-funded in the context of
Annual average MR adherence (n = 115) Figure 2
Annual average MR adherence (n = 115).
0
10
20
30
40
50
60
70
80
90
100
<80% 80-89% 90-94% ≥95%
Adherence Assessment by Medication Return (MR)
P
e
r
c
e
n
t
 
o
f
 
c
h
i
l
d
r
e
n
 BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
Page 8 of 12
(page number not for citation purposes)
no access to ART through government health services so
caregivers may have felt that ART was a privilege. Moreo-
ver, regular adherence monitoring may have enhanced
adherence. While the halving of the proportion of chil-
dren with MR adherence <90% during the year supports
this, it is a problem inherent to all adherence studies. In
addition, the actual estimate of adherence may be inflated
by use of clinic-based medication measures. The finding
by Muller et al.[29] of much lower adherence using MEMS
caps in a recent post-national ART roll-out study in a sim-
ilar setting to ours supports the likelihood of both partic-
ularly good adherence in our cohort, and of adherence
being over-estimated by our method of measurement.
Nevertheless, the strong association with viral suppres-
sion in our study indicates at least reasonable accuracy of
adherence measurement.
In contrast, reported NFA showed no relationship to viral
outcome and was only 32% sensitive for MR adherence
<90%. While the failure to find an association with viral
suppression may well be due to the fact that reported
adherence was only measured once long before viral load
measurement, the tendency for caregivers and patients to
over-estimate adherence is well estab-
lished.[15,23,28,29,32] In our study, this may have been
exacerbated by interviews being conducted by clinicians
to whom caregivers might be reluctant to admit to missing
doses, particularly in the context of limited access to ART.
This, however, reflects clinical practice.[15], and any
attempts to develop a screening tool for poor adherence in
busy roll-out clinics must take into account under-report-
ing of non-adherence to clinicians. In this study, the addi-
tional measuring of adherence by medication return
should have, at least in part, mitigated against under-
reporting.
Interestingly we found no association between MR adher-
ence in the month or 2 months immediately prior to viral
load measurement, in contrast to the strong association
with average MR adherence over the whole year. Other
studies have found strong associations between short-
term adherence and viral suppression immediately there-
after. [12,29] Having a single viral load measurement only
after a full year on treatment made it impossible to exam-
ine the effect of short-term fluctuations in adherence on
viral outcome. The small sample in this study may also
have reduced its power to show such an association par-
ticularly as a far smaller number of children than expected
had poor adherence. In addition, the sample size limited
the number of predictor variables that could be used in
Number of children in care at the end of each month on ART Figure 3
Number of children in care at the end of each month on ART. Total number of children in care at the end of each 
month divided into those returning and not returning medication
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analytic models. We were only able to include a single
indicator of disease severity in the model of viral suppres-
sion and only able to include socio-demographic and reg-
imen factors as predictors of MR adherence ≥ 90%.
It is notable that nearly 40% of caregivers experienced
problems with giving ART, and that this adversely affected
adherence over the whole year. Poor palatability of medi-
cation was the most common problem reported, espe-
cially in those taking ritonavir. This problem is unique to
infants and very young children taking liquid formula-
tions of drugs, and concurs with international stud-
ies.[18,22] A limitation of our study is that drug
formulation was not recorded so its effect on adherence
Changes in proportion with MR adherence <90% during the first year on ART Figure 4
Changes in proportion with MR adherence <90% during the first year on ART. Only children who remained alive 
and in care for entire first year of treatment (excludes children deceased or LFU; n = 88).
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Table 2: Univariate and multivariate factors associated with undetectable viral load (n = 88)
Variable Unadjusted OR 95%CI p-value Adjusted OR 95%CI p-value
Female gender 0.91 0.36 – 2.35 0.86 †
Age at treatment start (months) 1.00 0.99 – 1.01 0.81 †
WHO stage 2&3 (vs WHO stage 4) 2.80 1.07 – 7.35 0.04 *
Weight-for-age z-score 1.29 0.94 – 1.77 0.12 *
Height-for-age z-score 1.07 0.74 – 1.54 0.71 *
Weight-for-height z-score 1.94 1.27 – 2.96 0.002 1.8 1.15 – 2.80 0.01
CD4 percent 1.04 0.97 – 1.12 0.27 *
CD4 absolute (cells/l) 1.44 0.54 – 3.84 0.47 *
Log viral load 0.87 0.48 – 1.60 0.66 *
Ritonavir-containing regimen 0.33 0.13 – 0.87 0.03 †
Annual average MR adherence ≥ 90% 10.30 1.92 – 55.67 0.005 5.48 0.84 – 35.58 0.075
*Not included in building multivariate model
†Not significantly associated with viral suppression after adjustment for weight-for-height z-scoreBMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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could not be examined. However, the finding that a
greater proportion of children under 2 years of age (who
would all be taking liquid formulations) had adherence
>100% suggests that repeat dosing of syrups/solutions is
frequently necessary, placing an additional burden on car-
egivers.
It is further noteworthy that MR adherence results in the
ritonavir group appear paradoxical: taking ritonavir was
both negatively associated with (capped) MR adherence ≥
90%, and positively associated with (uncapped) MR
adherence >100%. The excess adherence is explained by
frequent need for repeat dosing. However poor adherence
in the ritonavir group when measures are capped indicates
that there is not always compliance with frequent dosing
with an unpalatable drug ultimately impacting negatively
on adherence. Indeed the poor adherence in the ritonavir
group was attributable to poor adherence to ritonavir
alone, with adherence to the other two drugs in the regi-
men being acceptable (data not shown). Although ritona-
vir is no longer used as a single third agent in ART
regimens, Kaletra® (lopinavir/ritonavir) is also unpalata-
ble and is recommended in the South African national
guidelines as part of the first-line regimen in children
under 3 years of age.[37] Moreover, drugs other than
ritonavir accounted for nearly a third of palatability prob-
lems. The need for pediatric-friendly formulations of ART
cannot be over-emphasized.
While some studies have suggested that older children are
more likely to be non-adherent, we found no relationship
between age and adherence.[20,30] However, in our study
the median age was young (36 months) with few children
approaching adolescence, so its potential negative effect
could not be determined. Nevertheless, it should be noted
that the age of children commencing ART at our institu-
tion has decreased since this initial program, with the
majority of children now being less than 2 year old.[8]
Our findings may therefore not be applicable to our cur-
rent patient cohort, and there is a need for further research
into adherence in very young infants in Africa.
While previous research in Africa has found little impact
of socio-economic status on adherence, our study suggests
that better caregiver education and socio-economic status
are both strongly independently associated with better
adherence. [16,25,27,29] Caregivers with secondary edu-
cation and those with access to water and electricity are
4.5 times and 2.7 times more likely to have adherence ≥
90% respectively. The lack of association between car-
egiver education and any of the indicators of socio-eco-
nomic status emphasizes that these both impact on
adherence and one is not simply a surrogate marker of the
other. Compared to adult ART, administering medication
to children, particularly infants, is more complex and
requires exact measurement of dosages, often to a fraction
of a milliliter, and compliance with stringent storage
requirements. In addition, unlike adults where dosage
remains constant over a long period, dosages for children
change frequently due to their rapid growth. Although we
did not examine the effect of complex dosages and dosage
changes on MR adherence, the positive impact on adher-
ence in children of better education and socio-economic
status of their caregivers is not surprising. However, the
failure to find an association with caregiver's ability to
describe a regimen and adherence suggests that it is the
caregiver's overall education that impacts more on treat-
ment adherence than treatment literacy per se.
Conclusion
This study demonstrates the potential for caregivers of
African young children to achieve adherence comparable
with that of wealthier countries. The association between
MR adherence and viral response attests to the value of a
relatively simple low technology tool for measuring
adherence i.e. clinic-based medication return for detecting
lapses in adherence. Nevertheless, repeated measure-
ments of medication returned, particularly of syrups/solu-
tions, are not feasible in most large program scale-up
settings and the poor sensitivity of low reported adher-
ence for low MR adherence highlights the need to develop
practical easy-to-use reliable screening tools to detect chil-
dren in whom more intensive adherence monitoring is
indicated. [30] The negative impact of problems experi-
enced with giving ART, unpalatable drugs, poor caregiver
Table 3: Factors associated with annual average MR adherence ≥ 90%. (n = 115)
Variable Unadjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Access to water and electricity 3.04 1.12 – 8.22 0.028 2.65 0.93 – 7.55 0.069
Formal housing 2.44 0.95 – 6.27 0.064 *
Access to working refrigerator 2.64 1.04 – 6.65 0.039 *
Secondary education (>Std 5/Grade 7) 3.84 1.06 – 13.98 0.041 4.49 1.10 – 18.24 0.035
Taking ritonavir 0.44 0.18 – 1.11 0.084 0.37 0.13 – 1.02 0.054
*Not included in multivariate model as only one measure of socio-economic status (access to water and electricity) used.BMC Pediatrics 2008, 8:34 http://www.biomedcentral.com/1471-2431/8/34
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education and socio-economic status on adherence in this
study underscores the need for more pediatric-friendly
drug formulations as well as the importance of supporting
caregivers in providing ART to children.
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